Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.33
AMAG's Cash to Debt is ranked higher than
61% of the 1244 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. AMAG: 2.33 )
AMAG' s 10-Year Cash to Debt Range
Min: 2.33   Max: No Debt
Current: 2.33

Equity to Asset 0.44
AMAG's Equity to Asset is ranked higher than
60% of the 933 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMAG: 0.44 )
AMAG' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.98
Current: 0.44

0.34
0.98
Interest Coverage No Debt
AMAG's Interest Coverage is ranked higher than
100% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMAG: No Debt )
AMAG' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 1.97
M-Score: -3.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -4.80
AMAG's Operating margin (%) is ranked higher than
82% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. AMAG: -4.80 )
AMAG' s 10-Year Operating margin (%) Range
Min: -18217.46   Max: 8.03
Current: -4.8

-18217.46
8.03
Net-margin (%) -11.68
AMAG's Net-margin (%) is ranked higher than
80% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.55 vs. AMAG: -11.68 )
AMAG' s 10-Year Net-margin (%) Range
Min: -15420.63   Max: 31.64
Current: -11.68

-15420.63
31.64
ROE (%) -5.84
AMAG's ROE (%) is ranked higher than
83% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. AMAG: -5.84 )
AMAG' s 10-Year ROE (%) Range
Min: -86.79   Max: 5.49
Current: -5.84

-86.79
5.49
ROA (%) -2.89
AMAG's ROA (%) is ranked higher than
84% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: -27.84 vs. AMAG: -2.89 )
AMAG' s 10-Year ROA (%) Range
Min: -67.05   Max: 3.34
Current: -2.89

-67.05
3.34
ROC (Joel Greenblatt) (%) -186.08
AMAG's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 1220 Companies
in the Global Biotechnology industry.

( Industry Median: -415.02 vs. AMAG: -186.08 )
AMAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1009.91   Max: 12.16
Current: -186.08

-1009.91
12.16
Revenue Growth (3Y)(%) 5.50
AMAG's Revenue Growth (3Y)(%) is ranked higher than
82% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. AMAG: 5.50 )
AMAG' s 10-Year Revenue Growth (3Y)(%) Range
Min: -31.2   Max: 265.9
Current: 5.5

-31.2
265.9
EBITDA Growth (3Y)(%) -53.50
AMAG's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. AMAG: -53.50 )
AMAG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -74.5   Max: 320.8
Current: -53.5

-74.5
320.8
EPS Growth (3Y)(%) -51.70
AMAG's EPS Growth (3Y)(%) is ranked higher than
55% of the 732 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. AMAG: -51.70 )
AMAG' s 10-Year EPS Growth (3Y)(%) Range
Min: -51.7   Max: 78.1
Current: -51.7

-51.7
78.1
» AMAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AMAG Guru Trades in Q4 2013

Jim Simons 40,176 sh (New)
Paul Tudor Jones 15,600 sh (New)
Steven Cohen 11,244 sh (New)
» More
Q1 2014

AMAG Guru Trades in Q1 2014

Jim Simons 125,160 sh (+211.53%)
Paul Tudor Jones 22,400 sh (+43.59%)
Steven Cohen Sold Out
» More
Q2 2014

AMAG Guru Trades in Q2 2014

Jim Simons 129,060 sh (+3.12%)
Paul Tudor Jones Sold Out
» More
Q3 2014

AMAG Guru Trades in Q3 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.76
AMAG's P/B is ranked higher than
77% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 6.37 vs. AMAG: 4.76 )
AMAG' s 10-Year P/B Range
Min: 1.12   Max: 18.97
Current: 4.76

1.12
18.97
P/S 10.26
AMAG's P/S is ranked higher than
82% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 29.14 vs. AMAG: 10.26 )
AMAG' s 10-Year P/S Range
Min: 3.62   Max: 496.73
Current: 10.26

3.62
496.73
EV-to-EBIT -162.08
AMAG's EV-to-EBIT is ranked higher than
85% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMAG: -162.08 )
AMAG' s 10-Year EV-to-EBIT Range
Min: -183.1   Max: -0.2
Current: -162.08

-183.1
-0.2
Current Ratio 10.99
AMAG's Current Ratio is ranked higher than
88% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.71 vs. AMAG: 10.99 )
AMAG' s 10-Year Current Ratio Range
Min: 3.27   Max: 54.4
Current: 10.99

3.27
54.4
Quick Ratio 10.49
AMAG's Quick Ratio is ranked higher than
88% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. AMAG: 10.49 )
AMAG' s 10-Year Quick Ratio Range
Min: 3.02   Max: 54.33
Current: 10.49

3.02
54.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.12
AMAG's Price/Net Cash is ranked higher than
87% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 52.60 vs. AMAG: 7.12 )
AMAG' s 10-Year Price/Net Cash Range
Min: 1   Max: 147.92
Current: 7.12

1
147.92
Price/Net Current Asset Value 6.26
AMAG's Price/Net Current Asset Value is ranked higher than
87% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 31.80 vs. AMAG: 6.26 )
AMAG' s 10-Year Price/Net Current Asset Value Range
Min: 0.97   Max: 80.68
Current: 6.26

0.97
80.68
Price/Tangible Book 5.20
AMAG's Price/Tangible Book is ranked higher than
81% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. AMAG: 5.20 )
AMAG' s 10-Year Price/Tangible Book Range
Min: 0.78   Max: 11.36
Current: 5.2

0.78
11.36
Price/Median PS Value 0.41
AMAG's Price/Median PS Value is ranked higher than
95% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 2.24 vs. AMAG: 0.41 )
AMAG' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 66.5
Current: 0.41

0.13
66.5
Earnings Yield (Greenblatt) -0.60
AMAG's Earnings Yield (Greenblatt) is ranked higher than
85% of the 1217 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. AMAG: -0.60 )
AMAG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -0.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AMU.Germany,
AMAG Pharmaceuticals Inc is a Delaware corporation was founded in 1981. The Company is a specialty pharmaceutical company that markets Feraheme Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA, and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors who, in turn, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers and nephrology clinics. In addition, it also outsource a number of its product supply chain services to ICS, its third-party logistics provider, including services related to warehousing and inventory management, distribution, chargeback processing, accounts receivable management and customer service call center management. The Company is subject to extensive additional federal, state and foreign healthcare regulation, which includes but is not limited to, the Federal False Claims Act, the Federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, and their state analogues, and similar laws in countries outside of the U.S.
» More Articles for AMAG

Headlines

Articles On GuruFocus.com
AMAG Pharmaceuticals Inc. (AMAG) EVP, CFO David Arkowitz sells 2,705 Shares Feb 28 2011 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 230,011 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. (AMAG) CFO and Chief Business Officer David Arkowitz sells 4,459 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2009 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 5,000 Shares Aug 05 2009 

More From Other Websites
AMAG PHARMACEUTICALS INC. Files SEC form 8-K/A, Change in Directors or Principal Officers Dec 11 2014
Celldex's Glembatumumab Vedotin in Phase II for Melanoma Dec 05 2014
Bayer Files Hemophilia A Drug Marketing Application in EU Dec 05 2014
CytRx Falls on Written FDA Notice for Aldoxorubicin Study Dec 04 2014
Regeneron at 52-Week High on Eylea Priority Review Status Dec 04 2014
Oncolytics Files for Orphan Drug Designation for Reolysin Dec 03 2014
AMAG Pharma (AMAG) Shares March Higher, Can It Continue? Dec 03 2014
Mylan, Gilead Ink Deal for TAF-based HIV Drugs Dec 02 2014
Celgene Hits 52-Week High on Positive CHMP Opinion Dec 01 2014
Alexion's Soliris Gets Final Positive NICE Recommendation Nov 28 2014
Mylan (MYL) Sued By Baxter for Generic Filing of Brevibloc Nov 28 2014
Merge Healthcare, Primordial to Improve Radiology Solutions Nov 28 2014
Glaxo's Ebola Candidate Well-Tolerated in Early U.S. Study Nov 28 2014
uniQure N.V. (QURE) in Focus: Stock Soars 17.6% Nov 28 2014
Coronado Biosciences, Inc. (CNDO) in Focus: Stock Soars 17.6% Nov 28 2014
Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% Nov 28 2014
AMAG Pharmaceuticals (AMAG): Strong Industry, Solid Earnings Estimate Revisions Nov 28 2014
Prosensa Holding N.V. (RNA) Jumps: Stock Rises 8.6% Nov 28 2014
Alexion's (ALXN) Soliris Gets Orphan Drug Status in Japan Nov 26 2014
Isis Pharmaceuticals Earns Milestone on Study Initiation Nov 26 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK